Circulatory miRNA-155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development

Breast most cancers is a posh illness with a number of elements concerned in its pathophysiological improvement. genetic mutations of BRCA1, BRCA2 and p53 are among the many most well-studied elements. The position of different genetic elements like altered expression profiles, SNPs within the regulatory areas of various genes or epigenetic elements like promoter methylation and histone modifications are additionally effectively studied however no stable understanding is offered on distinct key gamers triggering malignancy in breast most cancers, (Phosphatase and tensin homolog) PTEN is understood to be an important tumor suppressor because it has been reported to be lacking or abnormally expressed in lots of most cancers cells.

Right here on this have been studied how PTEN is expressed in malignant and benign most cancers cells by investigating its expression profile and mobile location utilizing Immuno-fluorescence microscopy. On the similar time, quantitative research of the circulatory mi-RNAs associated to the downregulation of PTEN, particularly mir-21 and mir-155 have studied additionally. Sixty biopsy samples, forty have been recognized to be malignant and twenty have been benign. It has been discovered that PTEN is generally expressed in benign samples and its usually localized within the cell membrane, whereas in malignant samples the expression degree of PTEN is decrease or absent and it’s translocated to the cytoplasm.

Apparently the quantitative expression of circulatory mir-21 and mir-155 within the blood plasma of the corresponding sufferers confirmed a associated sample with greater expression in malignant samples, subsequently can it is clear that PTEN is within the cross-talk of genetics and epigenetic regulation in regard of the event of malignant breast most cancers. On the similar time, this examine confirms the significance of circulatory miRNAs as a biomarker for early breast most cancers detection.

 

Transcriptome-wide profiles of round RNA and RNA-binding protein interactions reveal results on round RNA biogenesis and most cancers pathway expression

Background: Round RNAs (circRNAs) are steady, usually extremely expressed RNA transcripts with potential to modulate different regulatory RNAs. Just a few circRNAs have been proven to bind RNA-binding proteins (RBPs); nonetheless, little is understood in regards to the prevalence and distribution of those interactions in several organic contexts.
Strategies: We conduct an in depth display of circRNA-RBP interactions within the ENCODE cell strains HepG2 and Okay562. We profile circRNAs in deep-sequenced whole RNA samples and analyze circRNA-RBP interactions utilizing a big set of eCLIP information with binding websites of 150 RBPs. We validate interactions for choose circRNAs and RBPs by performing RNA immunoprecipitation and functionally characterize our most attention-grabbing candidates by conducting knockdown research adopted by RNA-Seq.
Outcomes: We generate a complete catalog of circRNA-RBP interactions in HepG2 and Okay562 cells. We present that KHSRP binding websites are enriched in flanking introns of circRNAs and that KHSRP depletion impacts circRNA biogenesis. We determine circRNAs which might be extremely lined by RBP binding websites and experimentally validate particular person circRNA-RBP interactions. We present that circCDYL, a extremely expressed circRNA with scientific and useful implications in bladder most cancers, is sort of fully lined with GRWD1 binding websites in HepG2 cells, and that circCDYL depletion counteracts the impact of GRWD1 depletion. Moreover, we verify interactions between circCDYL and RBPs in bladder most cancers cells and exhibit that circCDYL depletion impacts hallmarks of most cancers and perturbs the expression of key most cancers genes, e.g., TP53. Lastly, we present that elevated ranges of circCDYL are related to total survival of bladder most cancers sufferers.
Conclusions: Our examine demonstrates transcriptome-wide and cell-type-specific circRNA-RBP interactions that would play necessary regulatory roles in tumorigenesis.
 Circulatory miRNA-155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development

Circulatory miRNA-155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development

Sudden tumor response to palliative pelvic radiotherapy in mismatch repair-deficient superior prostate most cancers: a case report

Background: Mismatch-repair-deficiency leading to microsatellite instability (MSI) could confer elevated radiosensitivity in regionally superior/metastatic tumors and thus radiotherapy (RT) probably may need a altering position in treating this subset of sufferers, alone or together with checkpoint inhibitors.
Case presentation: We report a 76 year-old Italian male affected person presenting with regionally superior undifferentiated prostate most cancers (LAPC), infiltrating bladder and rectum. Molecular evaluation revealed high-MSI with an altered expression of MSH2 and MSH6 at immunohistochemistry. Two months after 6 chemotherapy cycles with Docetaxel related to an LHRH analogue, a computed tomography scan confirmed steady illness. After palliative RT (30 Gy/10 fractions) directed to the tumor mass with a 3D-conformal setup, a follow-up computed tomography scan at eight weeks revealed a formidable response that remained steady at computed tomography after 9 months, with sustained biochemical response. To our information, that is the primary case of such a sustained response to low dose RT alone in high-MSI LAPC.

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (HRP)

MBS6244012-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (HRP)

MBS6244012-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (PE)

MBS6244545-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (PE)

MBS6244545-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (AP)

MBS6241881-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (AP)

MBS6241881-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (APC)

MBS6242414-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (APC)

MBS6242414-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (FITC)

MBS6243479-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (FITC)

MBS6243479-5x01mL 5x0.1mL
EUR 4310

Breast cancer

BR1008b each
EUR 306
Description: Breast cancer, lymph node metastatic carcinoma and adjacent normal tissue array, including pathology grade, TNM, clinical stage, and ER/PR/Her2 result, 100 cases/100 cores, replacing BR1008a

Breast cancer

BR724 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores

Breast cancer

BR725 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (Biotin)

MBS6242946-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (Biotin)

MBS6242946-5x01mL 5x0.1mL
EUR 4310

pAIB1 | Amplified in breast cancer 1 protein

AS10-1577 100 µl
EUR 479

SNCG (breast cancer-specific protein 1)

Mab-606071 0.1mg
EUR 240

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 405)

MBS6245078-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 405)

MBS6245078-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 490)

MBS6245611-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 490)

MBS6245611-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 550)

MBS6246144-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 550)

MBS6246144-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 650)

MBS6246677-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 650)

MBS6246677-5x01mL 5x0.1mL
EUR 4310

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 750)

MBS6247210-01mL 0.1(mL
EUR 990

BRCA2 (Breast Cancer Antigen, Early Onset Breast Ovarian Cancer Susceptibility Protein 2) (MaxLight 750)

MBS6247210-5x01mL 5x0.1mL
EUR 4310

Breast cancer with cancer adjacent breast tissue array

BC081116e each
EUR 306
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d

Breast Cancer Resistance Protein (BCRP, AGCG2)

MC-226 BXP-34 Ask for price

Breast cancer type 2 susceptibility protein

AP81131 1mg
EUR 2640

Breast cancer type 1 susceptibility protein

AP81321 1mg
EUR 2640

Breast cancer-overexpressed gene 1 protein

E8M1210-6 100ul
EUR 275
Description: Available in various conjugation types.

Breast cancer-overexpressed gene 1 protein

MBS8534541-01mL 0.1mL
EUR 345

Breast cancer-overexpressed gene 1 protein

MBS8534541-01mLAF405L 0.1mL(AF405L)
EUR 565

Breast cancer-overexpressed gene 1 protein

MBS8534541-01mLAF405S 0.1mL(AF405S)
EUR 565

Breast cancer-overexpressed gene 1 protein

MBS8534541-01mLAF610 0.1mL(AF610)
EUR 565

Breast cancer-overexpressed gene 1 protein

MBS8534541-01mLAF635 0.1mL(AF635)
EUR 565

Breast Cancer Metastasis Suppressor 1 Protein

20-abx263402
  • Ask for price
  • Ask for price
  • Ask for price
  • 2 µg
  • 10 ug
  • 100 ug

Breast Cancer Metastasis Suppressor 1 Protein

abx263402-1mg 1 mg
EUR 225

Breast Cancer Metastasis Suppressor 1 Protein

abx263402-2mg 2 mg
EUR 325

Breast Cancer Metastasis Suppressor 1 Protein

abx263402-5mg 5 mg
EUR 1600

Breast cancer ANTIESTROGEN resistance 3 protein

FP-0006 Each Ask for price

Breast Cancer Cell Protein 2 (BRCC2) Antibody

20-abx141388
  • Ask for price
  • Ask for price
  • Ask for price
  • 50 ul
  • 100 ul
  • 200 ul

Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR)

MBS623085-01mL 0.1mL
EUR 650

Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR)

MBS623085-5x01mL 5x0.1mL
EUR 2780

Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR)

MBS620047-002mg 0.02mg
EUR 580

Synuclein, gamma (Synuclein gamma, Gamma Synuclein, SNCG, SNCG Protein, Breast Cancer Specific Gene 1, Breast Cancer Specific Gene 1 Protein, BCSG1, Breast Cancer Specific Protein 1, Persyn, PRSN, Synoretin, SR)

MBS620047-5x002mg 5x0.02mg
EUR 2470

Breast cancer TMA

BR602 each
EUR 270
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections

Breast cancer with matched cancer adjacent breast tissue array

BR804b each
EUR 306
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a

Amplified In Breast Cancer 1 Protein (NCOA3) Antibody

abx011671-100g 100 µg Ask for price

Amplified In Breast Cancer 1 Protein (NCOA3) Antibody

abx011671-100ul 100 ul
EUR 493.2

Amplified In Breast Cancer 1 Protein (NCOA3) Antibody

abx011671-10g 10 µg
EUR 362.5

Amplified In Breast Cancer 1 Protein (NCOA3) Antibody

abx011671-200g 200 µg Ask for price

Anti-BCRP (Breast Cancer Resistance Protein) mAb

MC-236 BXP-21 Ask for price

Breast Cancer Exosome

P141-BR - Ask for price

SNCG (breast cancer-specific protein 1) Antibody

BF0110 200ul
EUR 540

SNCG (breast cancer-specific protein 1) Antibody

BF0110-100ul 100ul
EUR 210
Description: WB,IHC,ELISA

SNCG (breast cancer-specific protein 1) Antibody

BF0110-200ul 200ul Ask for price
Description: WB,IHC,ELISA

SNCG (breast cancer-specific protein 1) Antibody

BF0110-50ul 50ul
EUR 150
Description: WB,IHC,ELISA

SNCG Antibody (breast cancer-specific protein 1)

E10-20084 100μg/100μl
EUR 225
Description: Available in various conjugation types.

SNCG Antibody (breast cancer-specific protein 1)

MBS850341-01mg 0.1mg
EUR 305

SNCG Antibody (breast cancer-specific protein 1)

MBS850341-01mLAF405L 0.1mL(AF405L)
EUR 565

SNCG Antibody (breast cancer-specific protein 1)

MBS850341-01mLAF405S 0.1mL(AF405S)
EUR 565

SNCG Antibody (breast cancer-specific protein 1)

MBS850341-01mLAF610 0.1mL(AF610)
EUR 565

SNCG Antibody (breast cancer-specific protein 1)

MBS850341-01mLAF635 0.1mL(AF635)
EUR 565

CA15-3 Cancer Antigen (Breast Cancer)

MBS651656-50KUnits 50KUnits
EUR 1890

CA15-3 Cancer Antigen (Breast Cancer)

MBS651656-5x50KUnits 5x50KUnits
EUR 8345

Breast cancer anti-estrogen resistance protein 3

AP80733 1mg
EUR 2640

Breast cancer anti-estrogen resistance protein 3

AP80942 1mg
EUR 2640

Breast cancer anti-estrogen resistance protein 3

AP80994 1mg
EUR 2640

Breast Cancer Anti-Estrogen Resistance 1 Protein

abx262743-10mg 10 mg
EUR 325

Breast Cancer Anti-Estrogen Resistance 1 Protein

20-abx262743
  • Ask for price
  • Ask for price
  • Ask for price
  • 2 µg
  • 10 ug
  • 1 mg

Breast Cancer Anti-Estrogen Resistance 1 Protein

abx262743-25mg 25 mg
EUR 6575

Breast Cancer Anti-Estrogen Resistance 1 Protein

abx262743-5mg 5 mg
EUR 225

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx065606-100g 100 µg
EUR 662.5

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

20-abx065606
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx065606-10g 10 µg
EUR 250

Rat Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx065606-50g 50 µg
EUR 462.5

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx166163-100g 100 µg
EUR 637.5

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

20-abx166163
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx166163-10g 10 µg
EUR 237.5

Rat Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx166163-50g 50 µg
EUR 437.5

Breast cancer with breast tissue array

BR2085d each
EUR 546
Description: Breast cancer with breast tissue array, including pathology grad, TNM and clinical stage, 188 cases/208 cores, replacing BR2085c

Breast cancer with breast tissue array

BR246d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 12 cases/24 cores, replacing BR246c

Breast cancer with breast tissue array

BR482 each
EUR 198
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 24 cases/48 cores

Breast cancer with breast tissue array

BR720 each
EUR 270
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge (reference AJCC 7th version), 72 cases/72 cores

Breast cancer with breast tissue array

BC08118a each
EUR 258
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores (core size 1.0mm), replacing BC08118

Breast cancer with breast tissue array

T087d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c

Breast cancer with breast tissue array

T088d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T088c

Breast cancer membrane protein 11 precursor antibody

22294 100ul
EUR 479

Breast cancer type 2 susceptibility protein homolog

AP81066 1mg
EUR 2640

Breast cancer type 1 susceptibility protein homolog

AP81109 1mg
EUR 2640

Breast cancer type 1 susceptibility protein homolog

AP81150 1mg
EUR 2640

Breast cancer type 1 susceptibility protein homolog

AP81239 1mg
EUR 2640

Breast cancer type 1 susceptibility protein homolog

AP81415 1mg
EUR 2640

Human Breast Cancer Susceptibility Protein ELISA Kit

MBS3803297-10x96StripWells 10x96-Strip-Wells
EUR 6725

Human Breast Cancer Susceptibility Protein ELISA Kit

MBS3803297-48StripWells 48-Strip-Wells
EUR 550

Human Breast Cancer Susceptibility Protein ELISA Kit

MBS3803297-5x96StripWells 5x96-Strip-Wells
EUR 3420

Human Breast Cancer Susceptibility Protein ELISA Kit

MBS3803297-96StripWells 96-Strip-Wells
EUR 765

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx065605-100g 100 µg
EUR 700

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

20-abx065605
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx065605-10g 10 µg
EUR 250

Human Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx065605-50g 50 µg
EUR 475

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx065607-100g 100 µg
EUR 612.5

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

20-abx065607
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx065607-10g 10 µg
EUR 237.5

Human Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx065607-50g 50 µg
EUR 425

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx166161-100g 100 µg
EUR 612.5

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

20-abx166161
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx166161-10g 10 µg
EUR 237.5

Mouse Breast Cancer Susceptibility Protein 1 (BRCA1) Protein

abx166161-50g 50 µg
EUR 425

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx166162-100g 100 µg
EUR 612.5

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

20-abx166162
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx166162-10g 10 µg
EUR 237.5

Mouse Breast Cancer Susceptibility Protein 2 (BRCA2) Protein

abx166162-50g 50 µg
EUR 425

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx129675-100l 100 µl
EUR 262.5

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx129675
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx129675-1ml 1 ml
EUR 725

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx129675-200l 200 µl
EUR 337.5

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

abx129746-100l 100 µl
EUR 262.5

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx129746
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

abx129746-1ml 1 ml
EUR 725

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

abx129746-200l 200 µl
EUR 337.5

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

abx130340-100l 100 µl
EUR 275

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx130340
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

abx130340-1ml 1 ml
EUR 775

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

abx130340-200l 200 µl
EUR 350

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx104049-100g 100 µg
EUR 712.5

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx104049
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx104049-20g 20 µg
EUR 262.5

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx104049-50g 50 µg
EUR 325

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx104050-100g 100 µg
EUR 775

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx104050
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx104050-20g 20 µg
EUR 275

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx104050-50g 50 µg
EUR 350

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx104051
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

Breast Cancer Susceptibility Protein 2 (BRCA2) Antibody

20-abx175628
  • Ask for price
  • Ask for price
  • 200 ug
  • 1 mg

Breast cancer-overexpressed gene 1 protein Antibody

48092 100ul
EUR 429

Breast cancer-overexpressed gene 1 protein Antibody

48092-100ul 100ul
EUR 399.6

Breast cancer-overexpressed gene 1 protein Antibody

48092-50ul 50ul
EUR 286.8

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx171476-100l 100 µl
EUR 750

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

20-abx171476
  • Ask for price
  • Ask for price
  • 200 ug
  • 1 mg

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx171476-1ml 1 ml Ask for price

Breast Cancer Susceptibility Protein 1 (BRCA1) Antibody

abx171476-200l 200 µl Ask for price
Conclusions: Routine analysis of MSI in sufferers with regionally problematic superior tumors would possibly change therapy technique and therapy purpose on this setting, from a purely palliative strategy to a quasi-curative paradigm.